Brilinta met primary endpoint in Phase III THALES trial in stroke
Brilinta reduced the risk of the composite of stroke and death after an acute ischaemic stroke or transient ischaemic attackHigh-level results from the Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone. THALES was conducted in over 11,000 patients who had a minor acute ischaemic stroke or high-risk transient ischaemic attack (TIA) in the 24 hours prior